Form 4 for RCKT ROCKET PHARMACEUTICALS, INC.
Accepted 2022-02-08 00:00:00 ET · period of report 2022-02-07 · accession 0001140361-22-004209 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-08 | 2022-02-07 | RCKT | Shah Gaurav | CEO, Dir | P - Purchase | $17.34 | +22.0K | 517.6K | +4% | +$381.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-07 | P | A | 22,000 | $17.34 | 517,639 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.03 to $17.50, inclusive. The reporting person undertakes to provide to Rocket Pharmaceuticals, Inc. ("RCKT"), any security holder of RCKT, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. |